• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
Jon Stonehouse, BioCryst CEO
October 14, 2025 11:13 AM EDTUpdated October 17, 08:45 AM
Deals

BioCryst to ac­quire As­tria for $700M, adding a sec­ond HAE drug

Elizabeth Cairns

Senior biopharma journalist

BioCryst Phar­ma­ceu­ti­cals plans to buy As­tria Ther­a­peu­tics for around $700 mil­lion in cash and stock.

The deal, an­nounced Tues­day, means BioCryst …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • Ro­bot­ic pill mak­er Rani teams up with Chugai in deal worth up to $1.08B October 17, 2025
  • Roche inks $80M up­front deal for Han­soh’s can­cer ADC October 17, 2025
  • White House makes new ‘most fa­vored na­tion’ deal, shares up­dates on FDA vouch­ers, GLP-1 ne­go­ti­a­tions October 16, 2025
TRENDING NOW

Sanofi, Ora­no Med’s ra­dio­phar­ma­ceu­ti­cal looks com­pet­i­tive in rare can­cer

In its first clin­i­cal read­out, Iambic shows ear­ly promise for AI-de­signed can­cer drug

Up­dat­ed: Ex­elix­is says TKI ex­tend­ed sur­vival in Phase 3 col­orec­tal can­cer tri­al 

Up­dat­ed: Roche claims its SERD is ‘most po­tent’ af­ter da­ta in breast can­cer all-com­ers

An­ti-ag­ing biotech NewLim­it brings in Eli Lil­ly as in­vestor, rais­ing $45M

Roche’s eye drug yields one hit, one miss in piv­otal tri­als

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times